▁he ▁super vis es ▁clin ical ▁academ ics . ▁He ▁also ▁super vis es ▁junior ▁do ctors ▁training ▁in ▁o ph th al mic ▁surg ery ▁and ▁D Ph il ▁research ▁students . ▁ ▁Business ▁In ▁ 2 0 1 4 , ▁with ▁Oxford ▁University , ▁he ▁co - f ounded ▁the ▁private ▁bio - techn ology ▁company ▁Night sta R x ▁Ltd ., ▁also ▁known ▁Night star , ▁in ▁which ▁he ▁remains ▁a ▁director , ▁and ▁which ▁is ▁based ▁at ▁the ▁offices ▁of ▁the ▁Well come ▁Trust ▁in ▁London . ▁ ▁The ▁technology ▁spin - out ▁was ▁developed ▁with ▁Oxford ▁In nov ation , ▁Ltd . ▁and ▁Syn con a ▁Ltd . ▁and ▁the ▁clin ical - stage ▁company ▁now ▁is ▁back ed ▁by ▁Syn con a , ▁NE A ▁vent ure ▁capital ▁and ▁Oxford ▁Science ▁Equ ity - Management ▁( O SE M ). ▁▁ ▁It ▁was ▁formed ▁to ▁develop ▁commercial ▁gene ▁ther apy ▁treat ments ▁to ▁treat ▁ch oro ider emia ▁– ▁an ▁inherited ▁cause ▁of ▁blind ness ▁affect ing ▁ 1 ▁in ▁ 5 0 , ▁ 0 0 0 ▁– ▁and ▁other ▁forms ▁of ▁inherited ▁ret inal ▁d yst ro phy . ▁The ▁company ▁has ▁received ▁four ▁r ounds ▁of ▁fund ing , ▁including ▁its ▁IP O ▁on ▁NAS DA Q ▁in ▁September ▁ 2 0 1 7 . ▁ ▁Military ▁ ▁Professor ▁Mac L aren ▁is ▁also ▁a ▁commission ed ▁officer ▁in ▁Group ▁A ▁– ▁the ▁units ▁intended ▁for ▁oper ational ▁service ▁– ▁of ▁the ▁Territ orial